Skip to main content
. Author manuscript; available in PMC: 2017 Sep 1.
Published in final edited form as: Leuk Lymphoma. 2016 Jan 19;57(9):2100–2108. doi: 10.3109/10428194.2015.1135435

Figure 1.

Figure 1

Disease response (upper panels) and survival (lower panels) A. Patients who received midostaurin and bortezomib (DLs 1 and 2); B. Patients who received midostaurin and bortezomib and MEC (DLs 3, 3*, 3A and 4). CR, complete remission; CRi, CR with incomplete count recovery (neutrophil or platelet); NR, non- responders